Complement C1s

Complement C1s

Complement C1s Molekülinformation

Molecule Name
Complement C1s
Molekülalias
EDSPD2
Drug Development Progress
Anzahl der klinischen Arzneimittel5
Anzahl der inverkehr gebrachten Arzneimittel4
Höchste Forschungs- und EntwicklungsphaseApproved
Target-Alias
EC:3.4.21.42,EC 3.4.21,C1 esterase,Complement component 1 subcomponent s,C1S,Complement C1s,Complement Component 1, S Subcomponent,Basic Proline-Rich Peptide IB-1,Complement C1s Subcomponent,EC 3.4.21.42,EDSPD2
Molekülhintergrund
Complement C1s is a serine protease and a key component of the C1 complex in the classical complement pathway. One C1q molecule binds to a tetramer composed of two C1r and two C1s proteases to form the intact C1 complex. C1s circulates as a zymogen until activated by proteolytic cleavage from activated C1r. Its essential function is to cleave complement components C4 and C2, thereby initiating the formation of the C3 convertase (C4b2a). This step is critical for triggering downstream immune effector functions, including opsonization, inflammation, and membrane attack complex formation.

Complement C1s Produktliste

Species
  • Cynomolgus(1)
  • Human(1)
Tag
  • His Tag(2)
Host
  • HEK293(2)
Conjugate
  • Unconjugated(2)
Grade
  • RUO(2)
Low Endotoxin
  • Yes(2)
MoleculeCat. No.Product NameArtHostStructurePurityActivitySize&PriceAdd to Cart
Complement C1s
Cynomolgus Complement C1s Protein, His Tag, low endotoxin (MALS verified)
Cynomolgus
HEK293
MALSSDS-PAGE
ELISA

$395.00

100ug
Complement C1s
Human Complement C1s Protein, His Tag, low endotoxin (MALS verified)
Human
HEK293
MALSSDS-PAGE
Enzyme

$395.00

100ug
You Have Viewed 1-2 Of 2 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Asset Licensing Opportunity
Resources

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
Complement-C1 inhibitor protein (Octapharma)Phase 3 ClinicalOctapharma
Angioedemas, Hereditary
Details
RiliprubartBIVV-020; SAR-445088; TNT-020Phase 3 ClinicalTrue North Therapeutics
Anemia, Hemolytic, Autoimmune; Graft Rejection; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; Purpura, Thrombocytopenic, Idiopathic
Details
C1 esterase inhibitor (Boya Bio-Pharmaceutical)Phase 3 ClinicalBoya Bio-Pharmaceutical Group Co Ltd
Angioedemas, Hereditary
Details
ClaseprubartDNTH103; DNTH-103Phase 3 ClinicalDianthus Therapeutics Inc
Autoimmune Diseases; Motor Neuron Disease; Multifocal Motor Neuropathy; Myasthenia Gravis; Nervous System Diseases; Polyradiculoneuropathy; Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
Details
C1 esterase inhibitor (Chengdu Institute of Biological Products)Phase 1 ClinicalChengdu Institute Of Biological Products Co Ltd
Angioedemas, Hereditary
Details

Inverkehr gebrachte Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaFrühestes MarkennameFrühestes GenehmigungslandFrüheste IndikationFrüheste GenehmigungsgesellschaftFrüheste GenehmigungsdatumIndikationenKlinische Studie
Conestat alfarhC1-INHApprovedPharming Group NvRhucin, Esterasine, RuconestEUAngioedemas, HereditaryPharming Group Nv2010-10-28
Angioedema; Angioedemas, Hereditary; Coronavirus Disease 2019 (COVID-19); Coronavirus Infections; Fatigue Syndrome, Chronic; Genetic Diseases, Inborn; Graft Rejection; Non-ST Elevated Myocardial Infarction; Rejection of renal transplantation; Renal Insufficiency
Details
SutimlimabBIVV-009; TNT-009ApprovedTrue North TherapeuticsENJAYMOUnited StatesAnemia, Hemolytic, AutoimmuneRecordati Rare Diseases Inc2022-02-04
Anemia, Hemolytic, Autoimmune; Clostridium Infections; Hemolysis; Kidney Failure, Chronic; Pemphigoid, Bullous; Purpura, Thrombocytopenic, Idiopathic
Details
Complement C1 inhibitor protein (Shire ViroPharma)C1 INH-nf; C1-INH; SHP-616ApprovedSanquin Plasma Products BvCinryze, CetorUnited StatesAngioedemas, Hereditarynull2008-10-10
Angioedemas, Hereditary; Brain Injuries, Traumatic; Graft Rejection; Rejection of organ transplantation
Details
C1 esterase inhibitor (Human, CSL Behring)BI-3.012; CSL-830; CSL-842; CE-1145ApprovedCsl Behring LlcBerinert, Haegarda, Berinert 2000JapanAngioedemas, HereditaryCsl Behring Llc1990-06-29
Angioedemas, Hereditary; Hereditary Angioedema Types I and II; Rejection of renal transplantation
Details
Customer Reviews